Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Mecca Cola is in direct competition with Coca-cola, deliberately appealing to anti-US sentiments. This growing tendency for manufacturers to market themselves on a political positioning to take advantage of consumer concerns creates a loyal customer base that will not be easily swayed.
Published By Datamonitor
|
09 Jan 2003 |
|
CommentWire
|
In the wake of large-scale outflows from money market funds late last year, Datamonitor argued that investors' fears around this fund class were unjustified, and predicted significant movements of cash back into the category. The latest data shows that we were right: money market funds are back in fashion, although they will have to fight for investors' attention during 2009.
Published By Datamonitor
|
29 Jan 2009 |
|
CommentWire
|
Selling formula baby milk to mothers in developing nations to replace breast milk has long been a touchy issue. As consumers become ever more suspicious of the motives of big business, some companies have allegedly still not mended their ways, courting bad press every time they reappear in the headlines.
Published By Datamonitor
|
21 Jan 2003 |
|
CommentWire
|
The Nigerian government has handed over control of its notoriously inefficient and corrupt state-run telecom operator to a Dutch telecoms consultancy, with a view to a later IPO. The consultancy, Pentascope International, may have to ensure heavy investment in the network to meet its contractual obligations.
Published By Datamonitor
|
20 Mar 2003 |
|
CommentWire
|
The price of Brent crude futures has risen by $7 per barrel on the IPE in London since January, bringing calls for Opec to increase its output and prevent further rises. Those calls have been dismissed as premature, but the oil exporters' determination to control production may yet be tested in the coming months.
Published By Datamonitor
|
05 Apr 2002 |
|
Expert View
|
Although the credit crunch has left non-financial services companies, including those in the biotechnology industry, without cheap debt, the pharmaceutical industry avoided relying on this resource and has remained cash-rich. As a result, pharmaceutical companies should weather the financial storm and be able to make significant acquisitions, unlike their biotechnology counterparts.
Published By Datamonitor
|
09 Oct 2008 |
|
Expert View
|
Regulations in some industries dictate that data must be kept for long periods - potentially over 100 years, but many organizations do not consider long-term retention when archiving. However, if they do not take action now, when information has to be retrieved it may be unreadable, as the application that created it will certainly not exist, and the file format it was created in may be obsolete.
Published By Datamonitor
|
25 May 2007 |
|
CommentWire
|
The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.
Published By Datamonitor
|
21 Nov 2001 |
|
Expert View
|
Even in the electronic age, there are still organizations that, despite using electronic systems to manage their information, still print all documents and records, and maintain the paper version as the official record. Apart from the time wasted in delivering paper records from off-site storage facilities back to the organization, there are inherent risks in maintaining paper-based records.
Published By Datamonitor
|
11 May 2007 |
|
CommentWire
|
DiaPep277 has already shown strong trial results for type I diabetes, which is in some ways similar to LADA. This makes the new investigation seem worthwhile. Approval would provide a new treatment option for an often-misdiagnosed subcategory of diabetic patients. It would also greatly increase the market potential of the drug, by allowing access to a much larger patient population.
Published By Datamonitor
|
15 Jan 2002 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.